The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...